Generation Bio Co. filings document the regulatory record for GBIO’s biotechnology business and subsequent public-company status changes. Form 8-K disclosures cover quarterly operating results, material agreements, executive and governance changes, lease termination matters, equity compensation actions, and capital-structure items including the reverse stock split.
Form 25 and Form 15 records document exchange-listing and Exchange Act registration matters for the company’s common stock. Those filings address the removal of the common stock from Nasdaq listing and the certification and notice process for termination of registration or suspension of reporting duties.
Atlas Venture reporting persons filed Amendment No. 3 to a Schedule 13G/A stating they beneficially own 0 shares (0%) of Generation Bio Co. common stock (CUSIP 37148K100). The filing lists the Reporting Persons and principal address and is signed on 05/14/2026.
T. Rowe Price Associates, Inc. filed Amendment No. 8 to a Schedule 13G reporting its beneficial ownership of 209,641 shares of Generation Bio Co.3.1% of the class as of December 31, 2025.
T. Rowe Price reports sole voting and sole dispositive power over all 209,641 shares and no shared power. The firm states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Generation Bio.
Generation Bio Co. received an amended Schedule 13G from Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reporting their ownership of the company’s common stock. As of December 31, 2025, they beneficially owned 287,614 shares, representing 4.27% of Generation Bio’s outstanding common stock.
The filing states that certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds from these shares. The holders certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Generation Bio.
Generation Bio Co. received an amended Schedule 13G showing that Baselake Partners, LP, Baselake Management, LLC and David Paolella now report beneficial ownership of 0 shares of Generation Bio common stock, or 0% of the class.
The filing confirms they have no sole or shared voting or dispositive power over any Generation Bio shares and that they own 5 percent or less of the company’s common stock. The certifying parties state the securities were not acquired or held with the purpose or effect of changing or influencing control of Generation Bio.
Generation Bio Co. became a wholly owned subsidiary of XOMA Royalty Corporation after a merger completed on February 9, 2026. Under the merger agreement, each tendered Generation Bio common share was exchanged for $4.2913 in cash per share plus one non-tradeable contingent value right (CVR) per share.
Each CVR represents the right to receive potential future cash payments, with an estimated maximum contingent consideration of $25.01 per CVR, subject to specified terms and conditions. In connection with this transaction, Atlas Venture–affiliated funds that were 10% owners reported disposition of 711,193, 116,693 and 60 Generation Bio common shares, and reported owning zero shares afterward.
Generation Bio Co. director Catherine Stehman-Breen reported the disposition of her equity in connection with the company’s sale to XOMA Royalty Corporation. She tendered 4,752 shares of common stock, which were exchanged for $4.2913 in cash per share plus one non-tradeable contingent value right (CVR) per share, with an estimated maximum contingent cash payment of $25.01 per CVR. Following completion of the tender offer, XRA 7 Corp. merged into Generation Bio on February 9, 2026, making it a wholly owned subsidiary of XOMA Royalty. Her in-the-money stock options vested, were cancelled, and converted into cash based on the spread to the cash amount, while out-of-the-money options were cancelled for no consideration, leaving her with 0 shares and 0 options reported as beneficially owned.
Generation Bio Co. director Rowland Charles A Jr reported the cash-out of his equity as the company was acquired by XOMA Royalty Corporation. Under a merger agreement among Generation Bio, XOMA Royalty and XRA 7 Corp., shares of common stock tendered into the offer were exchanged for $4.2913 per share in cash plus one non-tradeable contingent value right (CVR) per share, with an estimated maximum contingent cash payment of up to $25.01 per CVR. Following completion of the tender offer, XRA 7 Corp. merged into Generation Bio on February 9, 2026, making Generation Bio a wholly owned subsidiary of XOMA Royalty.
Rowland Charles A Jr reported disposition of 53,475 shares of common stock and now holds zero shares directly. All reported stock options to purchase common stock were also disposed of, leaving no derivative securities beneficially owned. Options with exercise prices below the cash amount became fully vested and were cancelled in exchange for cash, while those with exercise prices at or above the cash amount were cancelled for no consideration.
Generation Bio Co. has been acquired by XOMA Royalty Corporation, and a director is reporting related share and option changes. Under the merger agreement, each share of Generation Bio common stock tendered before the offer deadline was exchanged for $4.2913 in cash per share plus one non-tradeable contingent value right (CVR), with an estimated maximum contingent cash consideration of $25.01 per CVR.
After the tender offer, XOMA’s subsidiary merged into Generation Bio on February 9, 2026, making Generation Bio a wholly owned subsidiary. Entities affiliated with director Jason P. Rhodes, including Atlas Venture funds, had their indirect holdings in Generation Bio common stock converted into the cash-and-CVR consideration, with Rhodes disclaiming beneficial ownership except for any pecuniary interest. In addition, his outstanding stock options were either cashed out if in-the-money or cancelled for no consideration if the exercise price was at or above the cash amount.